Farmas USA

TEVA

Veremos cómo se comporta hoy....de momento me he puesto el traje para tradearla ....😉

ACHN

Lo que te comentaba del Factor D:

Achillion Reports Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor 
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - 
- Global program expansion planned in PNH, C3G and IC-MPGN - 


"Our focus in early clinical development with ACH-4471 has been on achieving proof-of-concept via factor D inhibition, and we are pleased to report that we believe we have achieved this goal. The emerging interim results from our phase 2 PNH trial have demonstrated a dose response to treatment with what we believe to be meaningful improvements in LDH, hemoglobin, fatigue score and other markers of response. To date, orally administered ACH-4471 has been well tolerated in this PNH clinical trial with four patients enrolled and treated with ACH-4471, two of whom have now received more than four months of dosing," commented Milind S. Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We believe that inhibition of factor D represents a highly innovative and differentiated mechanism of action with the potential to address multiple diseases of the alternative pathway, including PNH, C3G, IC-MPGN and geographic atrophy, an advanced form of dry age-related macular degeneration." 

"I am very excited by the clinical performance of ACH-4471 in the first patients to receive treatment, particularly the improvements in hemoglobin and self reported well-being that have been observed in my patients," commented Peter Browett, M.D., Professor of Pathology, Haematologist, and principal investigator in the ACH-4471 phase 2 study. "The unique mechanism of action via factor D inhibition by ACH-4471 may also be able to control both intravascular breakdown of PNH red blood cells, as well as extravascular hemolysis, leading to improved patient outcomes."

Notas de la CC de ayer

NVAX

https://www.rankia.com/foros/bolsa/respuestas/3655660-novavax-eps-in-line-beats-on-revenue-aug-8-2017-4-09-pm-et-by-gaurav

y añadir que la proxima semana se reunen con BARDA para tema financiacion

Efecto Trump

quizas se den hoy esos $33 en RDUS, no? esperando a ver donde pesco. en el AH está a $36

Patron familiar en progreso? ... a ver ...

IBB

CEMP

Melinta will merge with a subsidiary of Cempra. The merger is expected to create a NASDAQ-listed company committed to discovering, developing and commercializing important anti-infective therapies for patients and physicians in areas of significant unmet need.

current Cempra shareholders will own approximately 48 percent of the combined company and current Melinta shareholders will own approximately 52 percent of the combined company.  The transaction has been approved by the board of directors of both companies. The merger is expected to close in the fourth quarter of 2017.

The board of directors of the combined company will have nine seats, with four appointed by Cempra and four appointed by Melinta, together with a newly appointed CEO.

Cempra is actively engaged with potential government and industry partners to identify non-dilutive funding to support the execution of a clinical safety study to support a response to the complete response letter (CRL) for its oral solithromycin new drug application (NDA) for CABP.  Cempra also has an ongoing ophthalmic development program for solithromycin and is completing preclinical work to support a potential IND filing in 2018 with the FDA.  Fusidic acid for ABSSSI continues to progress after completion of a successful Phase 3 study with a clear path to NDA submission. Radezolid, a next-generation oxazolidinone discovered by Melinta using its technology platform, is nearing Phase 1 completion in acne vulgaris, with potential for expansion to additional indications. Radezolid, which is being developed with a partner, represents the first novel antibiotic in the acne space in more than 30 years, and has potent activity against acne-causing pathogens, including resistant strains.  Melinta is also actively progressing compounds within its ESKAPE pathogen program.  Using a technology platform based on Nobel Prize-winning science that is licensed from Yale, Melinta has built an entirely new class of antibiotics targeting ESKAPE pathogens, the “superbugs” causing significant mortality risk to patients affected, and intends to nominate a clinical candidate from this program in 2018.

https://globenewswire.com/news-release/2017/08/09/1082518/0/en/Cempra-and-Melinta-Announce-Merger-to-Form-Leading-Vertically-Integrated-Commercial-Stage-Anti-Infectives-Company.html